The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease

Journal of Nutritional Biochemistry

Volumn 38, Issue , 2016, Pages 1-11

  Belkouch, Mounir ^a   Hachem, Mayssa ^a   Elgot, Abdeljalil ^b   Van, Amanda Lo ^a   Picq, Madeleine ^a   Guichardant, Michel ^a   Lagarde, Michel ^a   Bernoud Hubac, Nathalie ^a  

^a UNIVERSITÉ DE LYON   (France)

^b HASSAN 1ST UNIVERSITY   (Morocco)

Author keywords

Alzheimer's disease; ApoE e4; DHA; Neurodegeneration; Neuroprotection

Indexed keywords

CERVONIC ACID; CHOLESTEROL; DOCOSAHEXAENOIC ACID; NEUROPROTECTIVE AGENT;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN FUNCTION; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; REVIEW; ANIMAL; DIET THERAPY; DIETARY SUPPLEMENT; HEALTHY DIET; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; HEALTHY DIET; HUMANS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS;

EID: 84962680878     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2016.03.002     Document Type: Review

References (177)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
2. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
3. Michaelson D.M. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement 2014, 10:861-868.
4. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277:32046-32053.
5. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
6. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46:860-866.
7. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009, 35:352-358.
8. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807.
9. Hoozemans J., Veerhuis R., Rozemuller A.J., Eikelenboom P. The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications. Drugs Today (Barc) 2002, 38:429-443.
10. Colangelo V., Schurr J., Ball M.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002, 70:462-473.
11. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3:205-214.
12. Butterfield D.A., Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 2007, 12:61-72.
13. Hardy J. The shorter amyloid cascade hypothesis. Neurobiol Aging 1999, 20:85. [discussion 87].
14. Burdge G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004, 7:137-144.
15. Ouellet M., Emond V., Chen C.T., Julien C., Bourasset F., Oddo S., et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem Int 2009, 55:476-482.
16. Thies F., Pillon C., Moliere P., Lagarde M., Lecerf J. Preferential incorporation of sn-2 lysoPCDHA over unesterified DHA in the young rat brain. Am J Phys 1994, 267:1273-1279.
17. Bernoud N., Fenart L., Molière P., Dehouck M.P., Lagarde M., Cecchelli R., et al. Preferential transfer of 2-docosahexaenoyl-1-lysophosphatidylcholine through an in vitro blood-brain barrier over unesterified docosahexaenoic acid. J Neurochem 1999, 72:338-345.
18. Nguyen L.N., Ma D., Shui G., Wong P., Cazenave-Gassiot A., Zhang X., et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 2014, 509:503-506.
19. Hachem M., Géloën A., Van A.L., Foumaux B., Fenart L., Gosselet F., et al. Efficient docosahexaenoic acid uptake by the brain from a structured phospholipid. Mol Neurobiol 2015.
20. Kawakita E., Hashimoto M., Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139:991-997.
21. He C., Qu X., Cui L., Wang J., Kang J.X. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A 2009, 106:11370-11375.
22. Katakura M., Hashimoto M., Shahdat H.M., Gamoh S., Okui T., Matsuzaki K., et al. Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix-loop-helix transcription factors and cell cycle in neural stem cells. Neuroscience 2009, 160:651-660.
23. Dagai L., Peri-Naor R., Birk R.Z. Docosahexaenoic acid significantly stimulates immediate early response genes and neurite outgrowth. Neurochem Res 2009, 34:867-875.
24. Hashimoto M., Hossain S., Shimada T., Shido O. Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 2006, 33:934-939.
25. Barceló-Coblijn G., Högyes E., Kitajka K., Puskás L.G., Zvara A., Hackler L., et al. Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc Natl Acad Sci U S A 2003, 100:11321-11326.
26. Puskás L.G., Kitajka K., Nyakas C., Barcelo-Coblijn G., Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci U S A 2003, 100:1580-1585.
27. Söderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
28. McGahon B.M., Martin D.S., Horrobin D.F., Lynch M.A. Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 1999, 94:305-314.
29. Kyle D.J., Schaefer E., Patton G., Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999, 34.
30. Favrelère S., Stadelmann-Ingrand S., Huguet F., De Javel D., Piriou A., Tallineau C., et al. Age-related changes in ethanolamine glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol Aging 2000, 21:653-660.
31. Conquer J.A., Tierney M.C., Zecevic J., Bettger W.J., Fisher R.H. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000, 35:1305-1312.
32. Tully A.M., Roche H.M., Doyle R., Fallon C., Bruce I., Lawlor B., et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003, 89:483-489.
33. Cunnane S.C., Schneider J.A., Tangney C., Tremblay-Mercier J., Fortier M., Bennett D.A., et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2012, 29:691-697.
34. Afshordel S., Hagl S., Werner D., Röhner N., Kögel D., Bazan N.G., et al. Omega-3 polyunsaturated fatty acids improve mitochondrial dysfunction in brain aging - impact of Bcl-2 and NPD-1 like metabolites. Prostaglandins Leukot Essent Fatty Acids 2015, 92:23-31.
35. Urano S., Sato Y., Otonari T., Makabe S., Suzuki S., Ogata M., et al. Aging and oxidative stress in neurodegeneration. Biofactors 1998, 7:103-112.
36. Mohajeri M.H., Troesch B., Weber P. Inadequate supply of vitamins and DHA in the elderly: implications for brain aging and Alzheimer-type dementia. Nutrition 2015, 31:261-275.
37. Nourooz-Zadeh J., Liu E.H., Yhlen B., Anggård E.E., Halliwell B. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999, 72:734-740.
38. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts L.J., Morrow J.D., et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004, 128:117-124.
39. Montine T.J., Morrow J.D. Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol 2005, 166:1283-1289.
40. Cole G.M., Frautschy S.A. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr Health 2006, 18:249-259.
41. Bernoud-Hubac N., Davies S.S., Boutaud O., Montine T.J., Roberts L.J. Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of the neuroprostane pathway. J Biol Chem 2001, 276:30964-30970.
42. Davies S.S., Bodine C., Matafonova E., Pantazides B.G., Bernoud-Hubac, N., Harrison F.E., et al. Treatment with a γ-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice. J Alzheimers Dis 2011, 27:49-59.
43. Freund Levi Y., Vedin I., Cederholm T., Basun H., Faxén Irving G., Eriksdotter M., et al. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern Med 2014, 275:428-436.
44. Yurko-Mauro K., McCarthy D., Rom D., Nelson E.B., Ryan A.S., Blackwell A., et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010, 6:456-464.
45. Lopez L.B., Kritz-Silverstein D., Barrett Connor E. High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: the Rancho Bernardo study. J Nutr Health Aging 2011, 15:25-31.
46. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006, 63:1545-1550.
47. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003, 60:940-946.
48. Suzuki H., Park S.J., Tamura M., Ando S. Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: a comparison of sardine oil diet with palm oil diet. Mech Ageing Dev 1998, 101:119-128.
49. Molfino A., Gioia G., Rossi Fanelli F., Muscaritoli M. The role for dietary omega-3 fatty acids supplementation in older adults. Nutrients 2014, 6:4058-4073.
50. Yurko-Mauro K., Alexander D.D., Van Elswyk M.E. Docosahexaenoic acid and adult memory: a systematic review and meta-analysis. PLoS One 2015, 10(3):e0120391.
51. Lee L.K., Shahar S., Rajab Yusoff N.A., Jamal R.A., Then S.M. The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case-control study. J Nutr Biochem 2013, 24:803-808.
52. Su H.M. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem 2010, 21:364-373.
53. Chiu C.C., Su K.P., Cheng T.C., Liu H.C., Chang C.J., Dewey M.E., et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1538-1544.
54. Nurk E., Drevon C.A., Refsum H., Solvoll K., Vollset S.E., Nygård O., et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland health study. Am J Clin Nutr 2007, 86:1470-1478.
55. Kotani S., Sakaguchi E., Warashina S., Matsukawa N., Ishikura Y., Kiso Y., et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006, 56:159-164.
56. Gamoh S., Hashimoto M., Hossain S., Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 2001, 28:266-270.
57. Little S.J., Lynch M.A., Manku M., Nicolaou A. Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: a lipidomic analysis. Prostaglandins Leukot Essent Fatty Acids 2007, 77:155-162.
58. Jiang L.H., Shi Y., Wang L.S., Yang Z.R. The influence of orally administered docosahexaenoic acid on cognitive ability in aged mice. J Nutr Biochem 2009, 20:735-741.
59. Dyall S.C., Michael G.J., Michael-Titus A.T. Omega-3 fatty acids reverse age-related decreases in nuclear receptors and increase neurogenesis in old rats. J Neurosci Res 2010, 88:2091-2102.
60. Labrousse V.F., Nadjar A., Joffre C., Costes L., Aubert A., Grégoire S., et al. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 2012, 7(5):e36861.
61. Firlag M., Kamaszewski M., Gaca K., Adamek D., Bałasińska B. Theneuroprotective effect of long-term n-3 polyunsaturated fatty acids supplementation in the cerebral cortex and hippocampus of aging rats. Folia Neuropathol 2013, 51:235-242.
62. Jiang L.H., Yan S., Wang J., Liang Q.Y. Oral administration of docosahexaenoic acid activates the GDNF-MAPK-CERB pathway in hippocampus of natural aged rat. Pharm Biol 2013, 51:1188-1195.
63. Pan J.P., Zhang H.Q., Wei-Wang Y.F., Guo Y.F., Na-Xiao, Cao X.H., et al. Some subtypes of endocannabinoid/endovanilloid receptors mediate docosahexaenoic acid-induced enhanced spatial memory in rats. Brain Res 2011, 1412:18-27.
64. Tanabe Y., Hashimoto M., Sugioka K., Maruyama M., Fujii Y., Hagiwara R., et al. Improvement of spatial cognition with dietary docosahexaenoic acid is associated with an increase in Fos expression in rat CA1 hippocampus. Clin Exp Pharmacol Physiol 2004, 31:700-703.
65. Sakamoto T., Cansev M., Wurtman R.J. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007, 1182:50-59.
66. Chang P.K., Khatchadourian A., McKinney R.A., Maysinger D. Docosahexaenoic acid (DHA): a modulator of microglia activity and dendritic spine morphology. J Neuroinflammation 2015, 12:34.
67. Morishima-Kawashima M., Ihara Y. The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 1998, 37:15247-15253.
68. Cordy J.M., Hussain I., Dingwall, Hooper N.M., Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2003, 100:11735-11740.
69. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 2001, 98:5815-5820.
70. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
71. Perez S.E., Berg B.M., Moore K.A., He B., Counts S.E., Fritz J.J., et al. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res 2010, 88:1026-1040.
72. Wang P.Y., Chen J.J., Su H.M. Docosahexaenoic acid supplementation of primary rat hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid beta protein(42) and up-regulates cytoskeletal protein expression. J Nutr Biochem 2010, 21:345-350.
73. Hashimoto M., Shahdat H.M., Katakura M., Tanabe Y., Gamoh S., Miwa K., et al. Effects of docosahexaenoic acid on in vitro amyloid beta peptide 25-35 fibrillation. Biochim Biophys Acta 2009, 1791:289-296.
74. Hossain S., Hashimoto M., Katakura M., Miwa K., Shimada T., Shido O. Mechanism of docosahexaenoic acid-induced inhibition of in vitro Abeta1-42 fibrillation and Abeta1-42-induced toxicity in SH-S5Y5 cells. J Neurochem 2009, 111:568-579.
75. Hashimoto M., Katakura M., Hossain S., Rahman A., Shimada T., Shido O. Docosahexaenoic acid withstands the Aβ(25-35)-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem 2011, 22:22-29.
76. Zhao Y., Calon F., Julien C., Winkler J.W., Petasis N.A., Lukiw W.J., et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models. PLoS One 2011, 6(1):e15816.
77. Calon F., Lim G.P., Morihara T., Yang F., Ubeda O., Salem N., et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 2005, 22:617-626.
78. Sahlin C., Pettersson F.E., Nilsson L.N., Lannfelt L., Johansson A.S. Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci 2007, 26:882-889.
79. Torres M., Price S.L., Fiol-Deroque M.A., Marcilla-Etxenike A., Ahyayauch H., Barceló-Coblijn G., et al. Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer's disease. Biochim Biophys Acta 1838, 2014:1680-1692.
80. Robson L.G., Dyall S., Sidloff D., Michael-Titus A.T. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol Aging 2010, 31:678-687.
81. Calderon F., Kim H.Y. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem 2004, 90:979-988.
82. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 2000, 60:65-72.
83. Freir D.B., Holscher C., Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol 2001, 85:708-713.
84. Fujita S., Ikegaya Y., Nishikawa M., Nishiyama N., Matsuki N. Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A(2) inhibitor in rat hippocampal slices. Br J Pharmacol 2001, 132:1417-1422.
85. Nishikawa M., Kimura S., Akaike N. Facilitatory effect of docosahexaenoic acid on N-methyl-d-aspartate response in pyramidal neurones of rat cerebral cortex. J Physiol 1994, 475:83-93.
86. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009, 29:9078-9089.
87. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
88. Koh H., Noh M.Y., Kim S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res 2008, 1188:254-262.
89. Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K., et al. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett 1996, 203:33-36.
90. Shoji M., Iwakami N., Takeuchi S., Waragai M., Suzuki M., Kanazawa I., et al. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res 2000, 85:221-233.
91. Petursdottir A.L., Farr S.A., Morley J.E., Banks W.A., Skuladottir G.V. Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse. J Gerontol A Biol Sci Med Sci 2008, 63:1153-1160.
92. Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 2002, 81:1084-1091.
93. Hashimoto M., Hossain S., Agdul H., Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 1738, 2005:91-98.
94. Hashimoto M., Tanabe Y., Fujii Y., Kikuta T., Shibata H., Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 2005, 135:549-555.
95. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
96. Oksman M., Iivonen H., Hogyes E., Solvoll K., Vollset S.E., Nygård O., et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006, 23:563-572.
97. Hooijmans C.R., Van der Zee C.E., Dederen P.J., Brouwer K.M., Reijmer Y.D., van Groen T., et al. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 2009, 33:482-498.
98. Arsenault D., Julien C., Tremblay C., Calon F. DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS One 2011, 6(2):e17397.
99. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005, 25:3032-3040.
100. Lebbadi M., Julien C., Phivilay A., Tremblay C., Emond V., Kang J.X., et al. Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease. J Alzheimers Dis 2011, 27:853-869.
101. Sawamura N., Ko M., Yu W., Zou K., Hanada K., Suzuki T., et al. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem 2004, 279:11984-11991.
102. Green K.N., Martinez-Coria H., Khashwji H., Hall E.B., Yurko-Mauro K.A., Ellis L., et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007, 27:4385-4395.
103. Grimm M.O., Kuchenbecker J., Grösgen S., Burg V.K., Hundsdörfer B., Rothhaar T.L., et al. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 2011, 286:14028-14039.
104. Hashimoto M., Hossain S., Katakura M., Al Mamun A., Shido O. The binding of Aβ1-42 to lipid rafts of RBC is enhanced by dietary docosahexaenoic acid in rats: implicates to Alzheimer's disease. Biochim Biophys Acta 1848, 2015:1402-1409.
105. Fiol-deRoque M.A., Gutierrez-Lanza R., Terés S., Torres M., Barceló P., Rial R.V., et al. Cognitive recovery and restoration of cell proliferation in the dentate gyrus in the 5XFAD transgenic mice model of Alzheimer's disease following 2-hydroxy-DHA treatment. Biogerontology 2013, 14:763-775.
106. Demars M., Hu Y.S., Gadadhar A., Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J Neurosci Res 2010, 88:2103-2117.
107. Corrigan F.M., Horrobin D.F., Skinner E.R., Besson J.A., Cooper M.B. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 1998, 30:197-207.
108. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998, 23:81-88.
109. Mulder C., Wahlund L.O., Teerlink T., Blomberg M., Veerhuis R., van Kamp G.J., et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 2003, 110:949-955.
110. Martín V., Fabelo N., Santpere G., Puig B., Marín R., Ferrer I., et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 2010, 19:489-502.
111. Chan R.B., Oliveira T.G., Cortes E.P., Honig L.S., Duff K.E., Small S.A., et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 2012, 287:2678-2688.
112. Filippov V., Song M.A., Zhang K., Vinters H.V., Tung S., Kirsch W.M., et al. Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis 2012, 29:537-547.
113. Pernber Z., Blennow K., Bogdanovic N., Månsson J.E., Blomqvist M. Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. Dement Geriatr Cogn Disord 2012, 33:174-188.
114. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61:199-205.
115. Popp J., Meichsner S., Kölsch H., Lewczuk P., Maier W., Kornhuber J., et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem Pharmacol 2013, 86:37-42.
116. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000, 7:321-331.
117. Shie F.S., Jin L.W., Cook D.G., Leverenz J.B., LeBoeuf R.C. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002, 13:455-459.
118. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004, 41:7-10.
119. Yip C.M., Elton E.A., Darabie A.A., Morrison M.R., McLaurin J. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 2001, 311:723-734.
120. Lazar A.N., Bich C., Panchal M., Desbenoit N., Petit V.W., Touboul D., et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol 2013, 125:133-144.
121. Ehehalt, Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003, 160:113-123.
122. Rushworth J.V., Hooper N.M. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis 2010, 2011:603052.
123. Schneider A., Schulz-Schaeffer W., Hartmann T., Schulz J.B., Simons M. Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis 2006, 23:573-577.
124. Abramov A.Y., Ionov M., Pavlov E., Duchen M.R. Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: implications for Alzheimer's disease. Aging Cell 2011, 10:595-603.
125. Marquer C., Laine J., Dauphinot L., Hanbouch L., Lemercier-Neuillet C., Pierrot N., et al. Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. Mol Neurodegener 2014, 9:60.
126. Rahman A., Akterin S., Flores-Morales A., Crisby M., Kivipelto M., Schultzberg M., et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 2005, 579:6411-6416.
127. Glöckner F., Meske V., Lütjohann D., Ohm T.G. Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 2011, 70:292-301.
128. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998, 95:6460-6464.
129. Yao Z.X., Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J 2002, 16:1677-1699.
130. Howland D.S., Trusko S.P., Savage M.J., Reaume A.G., Lang D.M., Hirsch J.D., et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 1998, 273:16576-16582.
131. Barrett P.J., Song Y., Van Horn W.D., Hustedt E.J., Schafer J.M., Hadziselimovic A., et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012, 336:1168-1171.
132. Di Scala C., Yahi N., Lelièvre C., Garmy N., Chahinian H., Fantini J. Biochemical identification of a linear cholesterol-binding domain within Alzheimer's β amyloid peptide. ACS Chem Neurosci 2013, 4:509-517.
133. Liu Y., Peterson D.A., Schubert D. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci U S A 1998, 95:13266-13271.
134. Stillwell W., Shaikh S.R., Zerouga M., Siddiqui R., Wassall S.R. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 2005, 45:559-579.
135. Vandal M., Alata W., Tremblay C., Rioux-Perreault C., Salem N., Calon F., et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem 2014, 129:516-526.
136. Samieri C., Lorrain S., Buaud B., Vaysse C., Berr C., Peuchant E., et al. Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype. J Lipid Res 2013, 54:2559-2567.
137. Huang T.L., Zandi P.P., Tucker K.L., Fitzpatrick A.L., Kuller L.H., Fried L.P., et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005, 65:1409-1414.
138. Chouinard-Watkins R., Rioux-Perreault C., Fortier M., Tremblay-Mercier J., Zhang Y., Lawrence P., et al. Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoEε4 allele. Br J Nutr 2013, 110:1751-1759.
139. Barberger-Gateau P., Samieri C., Féart C., Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res 2011, 8:479-491.
140. Kariv-Inbal Z., Yacobson S., Berkecz R., Peter M., Janaky T., Lütjohann D., et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis 2012, 28:667-683.
141. Wood W.G., Li L., Müller W.E., Eckert G.P. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem 2014, 129:559-572.
142. Erickson M.A., Banks W.A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013, 33:1500-1513.
143. Hjorth E., Zhu M., Toro V.C., Vedin I., Palmblad J., Cederholm T., et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 2013, 35:697-713.
144. Serini S., Bizzarro A., Piccioni E., Fasano E., Rossi C., Lauria A., et al. EPA and DHA differentially affect in vitro inflammatory cytokine release by peripheral blood mononuclear cells from Alzheimer's patients. Curr Alzheimer Res 2012, 9:913-923.
145. Vedin I., Cederholm T., Freund Levi Y., Basun H., Garlind A., Faxén Irving G., et al. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 2008, 87:1616-1622.
146. Mizwicki M.T., Liu G., Fiala M., Magpantay L., Sayre J., Siani A., et al. 1α,25-Dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis 2013, 34:155-170.
147. Itoh T., Yamamoto K. Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:541-547.
148. Lengqvist J., Mata De Urquiza A., Bergman A.C., Willson T.M., Sjövall J., Perlmann T., et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor α ligand-binding domain. Mol Cell Proteomics 2004, 3:692-703.
149. Lee J.Y., Plakidas A., Lee W.H., Heikkinen A., Chanmugam P., Bray G., et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003, 44:479-486.
150. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
151. Collie-Duguid E.S., Wahle K.W. Inhibitory effect of fish oil N-3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Commun 1996, 220:969-974.
152. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., Smith M.A. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:631-641.
153. Ding Q., Dimayuga E., Keller J.N. Oxidative damage. protein synthesis, and protein degradation in Alzheimer's disease. Curr Alzheimer Res 2007, 4:73-79.
154. Mancuso M., Coppede F., Migliore L., Siciliano G., Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 2006, 10:59-73.
155. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002, 277:40302-40308.
156. Nelson T.J., Alkon D.L. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 2005, 280:7377-7387.
157. Nitta A., Fukuta T., Hasegawa T., Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 1997, 73:51-57.
158. Bazan N.G. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 2005, 15:159-166.
159. Ferrera P., Mercado-Gómez O., Silva-Aguilar M., Valverde M., Arias C. Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem Res 2008, 33:1509-1517.
160. Moreira P.I., Zhu X., Liu Q., Honda K., Siedlak S.L., Harris P.L., et al. Compensatory responses induced by oxidative stress in Alzheimer disease. Biol Res 2006, 39:7-13.
161. Akbar M., Calderon F., Wen Z., Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci 2005, 102:10858-10863.
162. Guo M., Stockert L., Akbar M., Kim H.Y. Neuronal specific increase of phosphatidylserine by docosahexaenoic acid. J Mol Neurosci 2007, 33:67-73.
163. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005, 115:2774-2783.
164. Calandria J.M., Mukherjee P.K., de Rivero Vaccari J.C., Zhu M., Petasis N.A., Bazan N.G. Ataxin-1 poly(Q)-induced proteotoxic stress and apoptosis are attenuated in neural cells by docosahexaenoicacid-derived neuroprotectin D1. J Biol Chem 2012, 287:23726-23739.
165. Kim H.Y., Akbar M., Lau A., Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 2000, 275:35215-35223.
166. Florent S., Malaplate-Armand C., Youssef I., Kriem B., Koziel V., Escanyé M.C., et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem 2006, 96:385-395.
167. Christensen D.Z., Bayer T.A., Wirths O. Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 2010, 31:1153-1163.
168. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M., et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 2002, 22:3234-3243.
169. de Wilde M.C., Penke B., van der Beek E.M., Kuipers A.A., Kamphuis P.J., Broersen L.M. Neuroprotective effects of a specific multi-nutrient intervention against Aβ42-induced toxicity in rats. J Alzheimers Dis 2011, 27:327-339.
170. Rao J.S., Ertley R.N., Lee H.J., DeMar J.C., Arnold J.T., Rapoport S.I., et al. N-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 2007, 12:36-46.
171. Rinaldi P., Polidori M.C., Metastasio A., Mariani E., Mattioli P., Cherubini A., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003, 24:915-919.
172. Johnson E.J., McDonald K., Caldarella S.M., Chung H.Y., Troen A.M., Snodderly D.M. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 2008, 11:75-83.
173. Wurtman R.J., Cansev M., Ulus I.H. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging 2009, 13:189-197.
174. Koivisto H., Grimm M.O., Rothhaar T.L., Berkecz R., Lütjohann D.D., Giniatullina R., et al. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. J Nutr Biochem 2014, 25:157-169.
175. Zerbi V., Jansen D., Wiesmann M., Fang X., Broersen L.M., Veltien A., et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. Neurobiol Aging 2014, 35:600-613.
176. Shinto L., Quinn J., Montine T., Dodge H.H., Woodward W., Baldauf-Wagner S., et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis 2014, 38:111-120.
177. Amtul Z., Keet M., Wang L., Merrifield P., Westaway D., Rozmahel R.F. DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet?. PLoS One 2011, 6(9):e24094.